Platelet activity and in vivo arterial thrombus formation in rats with mild hyperhomocysteinaemia

Blood Coagulation and Fibrinolysis

Volumn 13, Issue 8, 2002, Pages 683-689

  Fuglsang, Jens ^a   Stender, M ^a   Zhou, J ^a   Moller J ^a   Falk, E ^a   Ravn, H B ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Animal models; Arterial thrombosis; Homocysteine; Platelets; Rats

Indexed keywords

ADENOSINE DIPHOSPHATE; COLLAGEN; HOMOCYSTEINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY INJURY; ARTERY THROMBOSIS; ARTICLE; COMPUTER ASSISTED DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FEMORAL ARTERY; HYPERHOMOCYSTEINEMIA; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE RICH PLASMA; THROMBOCYTE VOLUME; THROMBOGENESIS; VIDEORECORDING;

ADENOSINE DIPHOSPHATE; ANIMALS; BLOOD PLATELETS; COLLAGEN; HOMOCYSTEINE; HYPERHOMOCYSTEINEMIA; MALE; PLATELET ACTIVATION; PLATELET COUNT; RATS; RATS, WISTAR; THROMBOSIS;

EID: 0036919592     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200212000-00003     Document Type: Article

References (50)

1. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation 1995; 92: 657-671.
2. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991; 324: 1149-1155.
3. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. JAMA 1997; 277: 1775-1781.
4. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, et al. Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989; 79: 1180-1188.
5. Israelsson B, Brattström LE, Hultberg BL. Homocysteine and myocardial infarction. Atherosclerosis 1988; 71: 227-233.
6. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet 1995; 346: 1395-1398.
7. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: Probable benefits of increasing folic acid intakes. JAMA 1995; 274: 1049-1057.
8. Graeber JE, Slott JH, Ulane RE, Schulman JD, Stuart MJ. Effect of homocysteine and homocystine on platelet and vascular arachidonic acid metabolism. Pediatr Res 1982; 16: 490-493.
9. Fryer RH, Wilson BD, Gubler DB, Fitzgerald LA, Rodgers GM. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler Thromb 1993; 13: 1327-1333.
10. Lentz SR, Sadler JE. Inhibition of thrombomodulin surface expression and protein C activation by the thrombogenic agent homocysteine. J Clin Invest 1991; 88: 1906-1914.
11. Wall RT, Harlan JM, Harker LA, Striker GE. Homocysteine-induced endothelial cell injury in vitro: A model for the study of vascular injury. Thromb Res 1980; 18: 113-121.
12. Nishio E, Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular smooth muscle cells: A possible role for hydrogen peroxide. Br J Pharmacol 1997; 122: 269-274.
13. Starkebaum G, Harlan JM. Endothelial cell injury due to copper-catalyzed hydrogen peroxide generation from homocysteine. J Clin Invest 1986; 77: 1370-1376.
14. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME. Promotion of vascular smooth muscle cell growth by homocysteine: A link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373.
15. Lubec B, Arbeiter K, Hoeger H, Lubec G. Increased cyclin dependent kinase in aortic tissue of rats fed homocysteine. Thromb Haemost 1996; 75: 542-545.
16. ISIS-2 Collaborative Group. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349-360.
17. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613-617.
18. Trip MD, Cats VM, van Capelle FJL, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549-1554.
19. Di Minno G, Davi G, Margaglione M, Cirillo F, Grandone E, Ciabattoni G, et al. Abnormally high thromboxane biosynthesis in homozygous homocystinuria. J Clin Invest 1993; 92: 1400-1406.
20. Harker LA, Slichter SJ, Scott CR, Ross R. Homocystinemia: Vascular injury and arterial thrombosis. N Engl J Med 1974; 291: 537-543.
21. Hilden M, Brandt NJ, Nilsson IM, Schønheyder F. Investigations of coagulation and fibrinolysis in homocystinuria. Acta Med Scand 1974; 195: 533-535.
22. Schimke RN, McKusick VA, Huang T, Pollack AD. Homocystinuria. Studies of 20 families with 38 affected members. JAMA 1965; 193: 711-719.
23. Randon J, Chignard M, Lecompte T, Dray F, Vargaftig BB. Methylation inhibitors impair collagen-induced activation of human platelets [Letter]. Thromb Haemost 1983; 50: 756.
24. Ungvari Z, Sarkadi-Nagy E, Bagi Z, Szollar L, Koller A. Simultaneously increased TxA2 activity in isolated arterioles and platelets of rats with hyperhomocysteinaemia. Arterioscler Thromb Vasc Biol 2000; 20: 1203-1208.
25. Uhlemann ER, TenPas JH, Lucky AW, Schulman JD, Mudd SH, Shulman NR. Platelet survival and morphology in homocystinuria due to cystathionine synthase deficiency. N Engl J Med 1976; 295: 1283-1286.
26. Ravn HB, Kristensen SD, Hjortdal VE, Thygesen K, Husted SE. Early administration of intravenous magnesium inhibits arterial thrombus formation. Arterioscler Thromb Vasc Biol 1997; 17: 3620-3625.
27. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929.
28. Møller J, Rasmussen K. Homocysteine in plasma: Stabilization of blood samples with fluoride. Clin Chem 1995; 41: 758-759.
29. Rasmussen K, Møller J, Lyngbak M, Holm Pedersen AM, Dybkjær L. Age- and gender-specific reference intervals for total homocysteine and methylmalonic acid in plasma before and after vitamin supplementation. Clin Chem 1996; 42: 630-636.
30. Nygård O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337: 230-236.
31. Morita H, Kurihara H, Yoshida S, Saito Y, Shindo T, Oh-hashi Y, et al. Diet-induced hyperhomocysteinemia exacerbates neointima formation in rat carotid arteries after balloon injury. Circulation 2001; 103: 133-139.
32. Böger RH, Bode-Böger SM, Sydow K, Heistad DD, Lentz SR. Plasma concentration of assymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1557-1564.
33. Ungvari Z, Pacher P, Rischák K, Szollar L, Koller A. Dysfunction of nitric oxide mediation in isolated rat arterioles with methionine diet-induced hyperhomocysteinemia. Arterioscler Thromb Vasc Biol 1999; 19: 1899-1904.
34. Eberhardt RT, Forgione MA, Cap A, Leopold JA, Rudd MA, Trolliet M, et al. Endothelial dysfunction in a murine model of mild hyperhomocyst(e)inemia. J Clin Invest 2000; 106: 483-491.
35. Majors A, Ehrhart A, Pezacka EH. Homocysteine as a risk factor for vascular disease. Arterioscler Thromb Vasc Biol 1997; 17: 2074-2081.
36. Ueland PM, Refsum H, Stabler SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: Methods and clinical applications. Clin Chem 1993; 39: 1764-1779.
37. Hajjar KA, Mauri L, Jacovina AT, Zhong F, Mirza UA, Padovan JC, Chait BT. Tissue plasminogen activator binding to annexin II tail domain. J Biol Chem 1998; 16: 9987-9993.
38. Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: A potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. Proc Natl Acad Sci USA 1992; 89: 10193-10197.
39. Rolland PH, Friggi A, Barlatier A, Piquet P, Latrille V, Faye MM, et al. Hyperhomocysteinemia-induced vascular damage in the minipig. Captopril-hydrochlorothiazide combination prevents elastic alterations. Circulation 1995; 91: 1161-1174.
40. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD. Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996; 98: 24-29.
41. Harker LA, Ross R, Slichter SJ, Scott CR. Homocystine-induced arteriosclerosis. The role of endothelial cell injury and platelet response in its genesis. J Clin Invest 1976; 58: 731-741.
42. Reddy GSR, Wilcken DEL. Experimental homocysteinemia in pigs: Comparison with studies in sixteen homocystinuric patients. Metabolism 1982; 31: 778-783.
43. Durand P, Lussier-Cacan S, Blache D. Acute methionine load-induced hyperhomocysteinemia enhances platelet aggregation, thromboxane biosynthesis, and macrophage-derived tissue factor activity in rats. FASEBJ 1997; 11: 1157-1168.
44. Thompson CB, Eaton KA, Princiotta SM, Rushin CA, Valeri CR. Size dependent platelet subpopulations: Relationship of platelet volume to ultrastructure, enzymatic activity, and function. Br J Haematol 1982; 50: 509-519.
45. McDonald L, Bray C, Field C, Love F, Davies B. Homocystinuria, thrombosis, and the blood-platelets. Lancet 1964; i: 745-746.
46. Carson NAJ, Carré IJ. Treatment of homocystinuria with pyridoxine. A preliminary study. Arch Dis Child 1969; 44: 387-392.
47. Durand P, Prost M, Blache D. Pro-thrombotic effects of a folic acid deficient diet in rat platelets and macrophages related to elevated homocysteine and decreased n-3 polyunsaturated fatty acids. Atherosclerosis 1996; 121: 231-243.
48. Davis JW, Flournoy LD, Phillips PE. Amino acids and collagen-induced platelet aggregation. Am J Dis Child 1975; 129: 1020-1021.
49. Stamler JS, Osborne JA, Jaraki O, Rabbani LE, Mullins M, Singel D, Loscalzo J. Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest 1993; 91: 308-318.
50. Fernández-Ortiz A, Badimon JJ, Falk E, Fuster V, Meyer B, Mailhac A, et al. Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture. J Am Coll Cardiol 1994; 23: 1562-1569.